Research programme: antibody therapeutics - GenmabAlternative Names: Duobody-CD3-CD20; Hexabody®-DR5/DR5
Latest Information Update: 15 Nov 2016
At a glance
- Originator Genmab
- Class Antibodies
- Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants; TRAIL receptor 2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Infections